Critical role of leukotriene B4 receptor signaling in mouse 3T3-L1 preadipocyte differentiation

Lipids in Health and Disease

Yoshinori Kamisaki¹  Takashi Yamashiro²  Atsushi Nakajima³  Yuka Murata¹  Koichiro Wada¹  Kae Hirata¹ 

[1] Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka 565-0871, Japan;Department of Orthodontics and Dentofacial Orthopedics, Graduate School of Dentistry, Osaka University, Suita, Osaka 565-0871, Japan;Gastroenterology Division, Yokohama City University School of Medicine, Yokohama, Kanagawa 236-0004, Japan

关键词: siRNA;    BLT;    Mouse 3T3-L1 fibroblasts;    Preadipocyte differentiation;    Leukotrienes;   

Others  :  834163
DOI  :  10.1186/1476-511X-12-122

 received in 2013-07-05, accepted in 2013-08-06,  发布年份 2013

【 摘 要 】

Background

Various inflammatory mediators related to obesity might be closely related to insulin resistance. Leukotrienes (LTs) are involved in inflammatory reactions. However, there are few reports regarding the role of LTs in adipocyte differentiation. Therefore, we investigated the role of leukotriene B₄ (LTB₄)-leukotriene receptor (BLT) signaling in mouse 3T3-L1 fibroblastic preadipocyte differentiation to mature adipocytes.

Methods

Mouse 3T3-L1 preadipocytes were treated with lipoxygenase (LOX) inhibitors, BLT antagonist, and small interfering RNA (siRNA) for BLT1 and BLT2 to block the LTB₄-BLT signaling pathway, then the adipocyte differentiation such as lipid accumulation and the increase in triglyceride was evaluated.

Results

Blockade of BLT signaling by treatment with a LOX inhibitor or a BLT antagonist suppressed preadipocyte differentiation into mature adipocytes. In addition, knockdown of BLT1 and BLT2 by siRNAs dramatically inhibited differentiation. These results indicate the LTB₄-BLT signaling pathway may positively regulate preadipocyte differentiation and be a rate-limiting system to control adipocyte differentiation.

Conclusions

The LTB₄-BLT signaling pathway provides a potent regulatory signal that accelerates the differentiation of mouse 3T3-L1 preadipocytes. Further investigations are necessary to confirm the exact role of LTB₄ and BLTs signaling pathways in preadipocyte differentiation.

【 授权许可】

   
2013 Hirata et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Fasshauer M, Paschke R: Regulation of adipocytokines and insulin resistance. Diabetologia 2003, 46:1594-1603.
• [2]Yudkin JS: Inflammation, obesity, and the metabolic syndrome. Horm Metab Res 2007, 39:707-709.
• [3]Schinner S, Ulgen F, Papewalis C, Schott M, Woelk A, Vidal-Puig A, Scherbaum WA: Regulation of insulin secretion, glucokinase gene transcription and beta cell proliferation by adipocyte-derived Wnt signaling molecules. Diabetologia 2008, 51:147-154.
• [4]Hillenbrand A, Knippschild U, Weiss M, Schrezenmeier H, Henne-Bruns D, Huber-Lang M, Wolf AM: Sepsis induced changes of adipocytes and cytokines – septic patients compared to morbidly obese patients. BMC Surgery 2010, 10:26. BioMed Central Full Text
• [5]Kadowaki T, Hara K, Yamauchi T, Terauchi T, Tobe K, Nagai R: Molecular mechanism of insulin resistance and obesity. Exp Biol Med 2003, 228:1111-1117.
• [6]Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN: Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 2004, 237:1171-1176.
• [7]Haeggstrom JZ: Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis. J Biol Chem 2004, 279:50639-50642.
• [8]Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T: A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997, 387:620-624.
• [9]Brink C, Dahlen SE, Drazen J, Evans JF, Hay DWP, Nicosia S, Serhan CN, Shimizu T, Yokomizo T: International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 2003, 55:195-227.
• [10]Claria J, Lee MH, Serhan CN: Aspirin-triggered lipoxins (15-epi-LX) are generated by human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 1996, 2:583-596.
• [11]McMahon B, Mitchell D, Shattock R, Martin F, Brady HR, Godson DC: Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J 2002, 16:1817-1819.
• [12]Wada K, Arita M, Nakajima A, Katayama K, Kudo C, Kamisaki Y, Serhan CN: Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem cell proliferation and differentiation. FASEB J 2006, 20:1785-1792.
• [13]Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM: mPPARgamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994, 8:1224-1234.
• [14]Katayama K, Wada K, Miyoshi H, Ohashi K, Tachibana M, Furuki R, Mizuguchi H, Hayakawa T, Nakajima A, Kadowaki T, Tsutsumi Y, Nakagawa S, Kamisaki Y, Mayumi T: RNA interfering approach for clarifying the PPARγ pathway using lentiviral vector expressing short hairpin RNA. FEBS Lett 2004, 560:178-182.
• [15]Green H, Kehinde O: Sublines of mouse 3T3 cells that accumulate lipid. Cell 1974, 1:113-116.
• [16]Green H, Meuth M: An established pre-adipose cell line and its differentiation in culture. Cell 1974, 3:127-133.
• [17]Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995, 83:813-819.
• [18]Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med 2004, 10:1-7.
• [19]Spite M, Hellmann J, Tang Y, Mathis SP, Kosuri M, Bhatnagar A, Jala VR, Haribabu B: Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. J Immunol 2011, 187:1942-1949.
• [20]Wada K, Nakajima A, Katayama K, Kudo C, Shibuya A, Kubota N, Terauchi Y, Tachibana M, Miyoshi H, Kamisaki Y, Mayumi T, Kadowaki T, Blumberg RS: Peroxisome proliferator-activated receptor gamma-mediated neural stem cell proliferation and differentiation. J Biol Chem 2006, 281:12673-12681.